CLBA1: A Protein Implicated in Cell Signaling and Disease (G122616)

Target Name: CLBA1

NCBI ID: G122616

CLBA1: A Protein Implicated in Cell Signaling and Disease

CLBA1 (Clathrin-Binding Box of Aftiphilin-Containing Protein 1) is a protein that is expressed in various cell types, including neurons, muscle cells, and blood vessels. It is made up of four structural domains: an N-terminus, a transmembrane region, a cytoplasmic tail, and a C-terminus. The N-terminus of CLBA1 contains a unique structural feature known as a clathrin-binding domain, which is composed of a variable number of amino acids that are involved in the interaction with clathrin, a protein that is known for its role in cell signaling.

The clathrin-binding domain of CLBA1 is highly conserved across different species, and is thought to be involved in the regulation of various cellular processes, including cell signaling, cytoskeletal organization, and intracellular transport. CLBA1 has been shown to interact with multiple clathrin subunits, including clathrin-1, -2, and -3, as well as with other proteins involved in the clathrin signaling pathway, such as tyrosine kinases and G protein-coupled receptors.

CLBA1 has also been shown to play a role in the regulation of cellular processes that are important for brain development and function, such as the migration of neurons and the formation of synapses. In addition, CLBA1 has been implicated in the regulation of cellular responses to various signaling systems, including TGF-β, NF-kappa-B, and PI3K.

Despite the potential importance of CLBA1 in cellular processes, little is known about its function or the specific roles that it plays in different cell types. However, its interaction with clathrin and other proteins involved in the clathrin signaling pathway suggest that it may be a drug target or biomarker for various diseases.

One potential drug target for CLBA1 is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the build-up of abnormal proteins, including CLBA1.

Another potential drug target for CLBA1 is the treatment of various types of cancer, including neuroblastoma and melanoma. These conditions are characterized by the rapid and uncontrolled growth of cancer cells, and the development of various signaling pathways that promote cell proliferation. CLBA1 has been shown to be involved in the regulation of cell signaling, and its potential as a drug target or biomarker makes it a promising target for the treatment of these conditions.

In addition to its potential drug-targeting potential, CLBA1 may also be a biomarker for certain diseases. For example, CLBA1 has been shown to be expressed in various types of cancer, including breast cancer, and may be used as a diagnostic marker for these conditions. Additionally, its interaction with clathrin and other proteins involved in the clathrin signaling pathway suggests that CLBA1 may be involved in the regulation of cellular processes that are important for cancer progression and the development of metastasis.

Overall, CLBA1 is a protein that has important roles in various cellular processes, including cell signaling and the regulation of cellular responses to different signaling systems. Its interaction with clathrin and other proteins suggests that it may be a drug target or biomarker for various diseases, including neurodegenerative conditions and cancer. Further research is needed to fully understand its functions and potential as a drug.

Protein Name: Clathrin Binding Box Of Aftiphilin Containing 1

More Common Targets